| Literature DB >> 1702172 |
Abstract
The novel macrolide immunosuppressant FK 506 is a powerful and selective anti-T-cell agent which has a similar mode of action to that of cyclosporin. Clinical studies of FK 506 in liver allograft recipients indicate a lower risk/benefit ratio than with cyclosporin, and wider evaluation of FK 506 in transplant recipients is now under way in multicentre, prospective, controlled trials in both Europe and North America.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1702172 DOI： 10.1016/0140-6736(91)93341-6
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321